自己免疫治療の世界市場レポート 2025年

自己免疫治療の市場規模は、今後数年で急成長が見込まれます。2029年にはCAGR14.1％で146億6,000万米ドルに成長します。予測期間の成長は、精密医療へのアプローチ、低分子療法の出現、新規経路の標的化、遺伝子治療の革新、バイオ医薬品投資の増加、バイオシミラー市場の成長に起因すると考えられます。予測期間の主な動向には、生物製剤と標的療法の進歩、免疫調節療法、希少自己免疫疾患への注目、遠隔医療と遠隔モニタリング、規制当局の取り組みと医薬品承認、デジタルヘルスツールの統合などが含まれます。

自己免疫治療市場は、自己免疫疾患をターゲットとする薬剤の研究開発（R&D）への投資増加により、大きな成長を遂げることが予想されます。R&Dの取り組みは、新製品やサービスのイノベーションとイントロダクションを促進します。具体的には、自己免疫疾患治療薬の研究開発努力により、より精密で低分子、経口活性で、十分に特性化された免疫抑制薬であり、忍容性のある長期治療プロファイルの創製が可能になります。特に、2022年1月、米国の大手製薬会社イーライリリー・アンド・カンパニーは、研究開発投資を2021年の70億米ドルから2022年には71億9,000万米ドルに引き上げ、売上高に占める研究開発費の割合を24.8%から25.19%に引き上げました。この研究開発投資の急増は、自己免疫治療市場の成長を促進します。

ヘルスケア支出の増加は、今後の自己免疫治療市場の成長を促進すると予測されています。ヘルスケア支出には、家族計画活動、栄養プログラム、緊急健康支援など、ヘルスケアサービスの提供に関連するすべての費用が含まれます。ヘルスケア支出の増加は、自己免疫疾患を治療するためのより効果的な治療法や医療技術の開発を促進すると考えられます。例えば、予算責任局（OBR）と財務省の経済予測によると、英国の計画医療費は2024/25年に1,920億GBP（2,444億3,000万米ドル）に上昇し、2022/23年の1,820億GBP（2,317億米ドル）から増加すると予測されています。同様に、米国の独立系医療政策調査機関KFFの国民医療費会計（NHEA）では、医療費は2023年から2024年にかけて5％成長し、4兆9,000億米ドルに達すると予測しています。したがって、ヘルスケア支出の増加が自己免疫治療市場の成長を促進しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の自己免疫治療PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の自己免疫治療市場：成長率分析
• 世界の自己免疫治療市場の実績：規模と成長, 2019-2024
• 世界の自己免疫治療市場の予測：規模と成長, 2024-2029, 2034F
• 世界の自己免疫治療総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の自己免疫治療市場：製品別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 消耗品およびアッセイキット
• 機器
• サービス
• 世界の自己免疫治療市場：サービスタイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 診察と診断
• 治療とモニタリング
• 医薬品開発
• 世界の自己免疫治療市場：疾患別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 関節リウマチ
• 全身性エリテマトーデス
• シェーグレン症候群
• 甲状腺炎
• 強皮症
• その他の疾患
• 世界の自己免疫治療市場：薬剤クラス別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 抗炎症
• 高血糖抑制
• NSAIDs
• インターフェロン
• その他の薬物クラス
• 世界の自己免疫治療市場：消耗品およびアッセイキットのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ELISAキット
• 試薬と抗体
• サンプル収集キット
• 世界の自己免疫治療市場：機器のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 診断機器
• イメージングシステム
• 世界の自己免疫治療市場：サービスのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 検査および診断サービス
• コンサルティングおよびサポートサービス
• データ分析および解釈サービス

第7章 地域別・国別分析

• 世界の自己免疫治療市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の自己免疫治療市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 自己免疫治療市場：競合情勢
• 自己免疫治療市場：企業プロファイル
  • Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
  • Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Hoffmann-La Roche AG
• AstraZeneca PLC
• Bristol-Myers Squibb Company
• Autoimmune Inc.
• Siemens Healthcare Private Limited
• Thermo Fisher Scientific Inc.
• Biogen Idec Inc.
• Bayer Schering Pharma AG
• GSK PLC
• Genentech Inc.
• AbbVie Inc.
• Celgene Corporation
• Gilead Sciences Inc.
• Merck & Co. Inc.
• Novartis International AG

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 自己免疫治療市場2029：新たな機会を提供する国
• 自己免疫治療市場2029：新たな機会を提供するセグメント
• 自己免疫治療市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Autoimmune treatment encompasses the strategic management and support provided to patients to address autoimmune diseases or disorders. In these conditions, the immune system targets the body's own cells. The application of autoimmune treatment aims to effectively address and manage autoimmune diseases.

In the realm of autoimmune treatment, the primary product categories comprise consumables and assay kits, instruments, and services. Consultation denotes the act of seeking guidance from physicians or healthcare professionals for diagnostic studies, therapeutic interventions, or related services. Diagnosis, on the other hand, involves the systematic identification of the nature of an illness or problem through the examination of signs and symptoms. The principal service types encompass consultation and diagnosis, therapy and monitoring, and drug development, with a focus on various diseases such as rheumatoid arthritis, systemic lupus erythematosus, sjogren's syndrome, thyroiditis, scleroderma, among others. Key drug classes integral to autoimmune treatment include anti-inflammatory agents, anti-hyperglycemics, NSAIDs, interferons, and others. Clinical laboratories, hospitals, and similar entities constitute the primary end users in this domain.

The autoimmune treatment market report is one of a series of new reports from The Business Research Company that provides autoimmune treatment statistics, including autoimmune treatment industry global market size, regional shares, competitors with an autoimmune treatment market share, detailed autoimmune treatment market segments, market trends and opportunities, and any further data you may need to thrive in the autoimmune treatment industry. This autoimmune treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The autoimmune treatment market size has grown rapidly in recent years. It will grow from $7.72 billion in 2024 to $8.66 billion in 2025 at a compound annual growth rate (CAGR) of 12.1%. The growth in the historic period can be attributed to increasing prevalence, advancements in immunology, genetic research insights, patient awareness and advocacy, regulatory support.

The autoimmune treatment market size is expected to see rapid growth in the next few years. It will grow to $14.66 billion in 2029 at a compound annual growth rate (CAGR) of 14.1%. The growth in the forecast period can be attributed to precision medicine approaches, emergence of small molecule therapies, targeting novel pathways, gene therapy innovations, increasing biopharmaceutical investments, biosimilar market growth. Major trends in the forecast period include advancements in biologics and targeted therapies, immunomodulatory therapies, focus on rare autoimmune diseases, telemedicine and remote monitoring, regulatory initiatives and drug approvals, integration of digital health tools.

The autoimmune treatment market is set to experience significant growth due to increased investments in research and development (R&D) for drugs targeting autoimmune diseases. R&D initiatives facilitate the innovation and introduction of new products and services. Specifically, R&D efforts in autoimmune disease drugs enable the creation of more precise, low-molecular-weight, orally active, and well-characterized immune suppressive drugs with tolerable long-term treatment profiles. Notably, in January 2022, Eli Lilly and Company, a US-based pharmaceutical giant, raised its R&D investment from $7 billion in 2021 to $7.19 billion in 2022, elevating its R&D expenditure as a percentage of revenue from 24.8% to 25.19%. This surge in R&D investments propels growth within the autoimmune treatment market.

The increasing healthcare expenditures are anticipated to drive the growth of the autoimmune treatment market in the future. Healthcare expenditures encompass all costs related to providing health services, including family planning activities, nutrition programs, and emergency health assistance. An uptick in healthcare spending is likely to facilitate the development of more effective therapies and medical technologies for treating autoimmune disorders. For example, the economic forecast from the Office for Budget Responsibility (OBR) and Treasury indicates that the UK's planned health expenditure is projected to rise to £192 billion ($244.43 billion) in 2024/25, an increase from £182 billion ($231.70 billion) in 2022/23. Similarly, the National Health Expenditures Accounts (NHEA) from KFF, an independent health policy research organization in the US, predict that health spending will grow by 5% from 2023 to 2024, reaching $4.9 trillion. Therefore, the increase in healthcare expenditures is fueling the growth of the autoimmune treatment market.

Technological advancements emerge as a pivotal trend shaping the landscape of the autoimmune treatment market. Major market players are actively investing in advanced technologies to solidify their positions. Notably, in June 2023, Belgium-based pharmaceutical company UCB received approval from the U.S. Food and Drug Administration (FDA) for RYSTIGGO (rozanolixizumab-noli) to treat generalized myasthenia gravis (gMG) in adults who test positive for anti-acetylcholine receptor (AchR) or anti-muscle-specific tyrosine kinase (MuSK) antibodies. This approval, expedited under Priority Review, marks RYSTIGGO as the exclusive FDA-approved therapy for both anti-AchR and anti-MuSK antibody-positive gMG, encompassing the two most prevalent subtypes of this autoimmune condition. This breakthrough signifies a potential enhancement in provider efficiency, treatment efficacy, and overall patient care within the autoimmune illness domain.

Prominent players in the autoimmune treatment market are intensifying their focus on introducing cutting-edge clinical trial platforms as a strategic move to gain a competitive advantage. These innovative platforms in autoimmune treatment capitalize on advanced technologies and personalized methodologies to enhance treatment efficacy, safety, and overall patient outcomes. For instance, in August 2023, the Scleroderma Research Foundation, a US-based non-profit organization, introduced the CONQUEST trial platform. This groundbreaking initiative aims to advance research and therapeutic approaches for scleroderma, a rare autoimmune disease impacting connective tissues. The CONQUEST program addresses pivotal challenges in clinical development, fostering advancements in scleroderma treatment methodologies. Notably, the CONQUEST platform clinical trial represents a pioneering effort in rare autoimmune diseases, specifically focusing on swiftly evaluating potential treatments for interstitial lung disease associated with systemic sclerosis (SSc-ILD) and overall SSc outcomes, encompassing aspects such as skin and other disease manifestations.

In another significant development in August 2023, Eli Lilly and Company, a US-based pharmaceutical giant, completed the acquisition of DICE Therapeutics, Inc. for $2.4 billion. This strategic acquisition expands Lilly's portfolio in the realm of immunology products by integrating DICE's innovative oral therapeutic candidates. Notably, DICE Therapeutics, Inc., a US-based pharmaceutical firm, specializes in developing novel oral therapies targeting autoimmune and inflammatory conditions. Specifically, DICE's oral IL-17 inhibitors, presently undergoing clinical development, are poised to offer innovative treatment approaches for chronic immunological disorders, broadening Lilly's offerings in this therapeutic domain.

Major companies operating in the autoimmune treatment market are Abbott Laboratories, Amgen Inc., Johnson & Johnson Services Inc., Eli Lilly and Company, Pfizer Inc., Hoffmann-La Roche AG, AstraZeneca PLC, Bristol-Myers Squibb Company, Autoimmune Inc., Siemens Healthcare Private Limited, Thermo Fisher Scientific Inc., Biogen Idec Inc., Bayer Schering Pharma AG, GSK PLC, Genentech Inc., AbbVie Inc., Celgene Corporation, Gilead Sciences Inc., Merck & Co. Inc., Novartis International AG, Sanofi SA, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., UCB SA, Alexion Pharmaceuticals Inc., Amarin Corporation PLC, AnaptysBio Inc., Apellis Pharmaceuticals Inc., Arena Pharmaceuticals Inc., Aurinia Pharmaceuticals Inc., BioCryst Pharmaceuticals Inc., Biohaven Pharmaceutical Holding Company Ltd., BioMarin Pharmaceutical Inc., bluebird bio Inc., Cabaletta Bio Inc., Catabasis Pharmaceuticals Inc., ChemoCentryx Inc., Coherus BioSciences Inc., Corbus Pharmaceuticals Holdings Inc., CSL Limited, Cumberland Pharmaceuticals Inc., CytoDyn Inc.

North America was the largest region in the autoimmune treatment market in 2024. The regions covered in the autoimmune treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the autoimmune treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The autoimmune treatment includes revenues earned by entities by providing immunosuppressive therapy, biological treatment, immuno-suppressing medications services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Autoimmune Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on autoimmune treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for autoimmune treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The autoimmune treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product: Consumables And Assay Kits; Instruments; Services
• 2) By Service Type: Consultation And Diagnosis; Therapy And monitoring; Drug development
• 3) By Disease: Rheumatoid Arthritis; Systemic Lupus Erythematosus; Sjogren's Syndrome; Thyroiditis; Scleroderma; Other Diseases
• 4) By Drug Class: Anti-Inflammatory; Anti-Hyperglycemic; NSAIDs; Interferons; Other Drug Class
• Subsegments:
• 1) By Consumables And Assay Kits: ELISA Kits; Reagents And Antibodies; Sample Collection Kits
• 2) By Instruments: Diagnostic Equipment; Imaging Systems
• 3) By Services: Testing And Diagnostics Services; Consultation And Support Services; Data Analysis And Interpretation Services
• Companies Mentioned: Abbott Laboratories; Amgen Inc.; Johnson & Johnson Services Inc.; Eli Lilly and Company; Pfizer Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Autoimmune Treatment Market Characteristics

3. Autoimmune Treatment Market Trends And Strategies

4. Autoimmune Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Autoimmune Treatment Growth Analysis And Strategic Analysis Framework

• 5.1. Global Autoimmune Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Autoimmune Treatment Market Growth Rate Analysis
• 5.4. Global Autoimmune Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Autoimmune Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Autoimmune Treatment Total Addressable Market (TAM)

6. Autoimmune Treatment Market Segmentation

• 6.1. Global Autoimmune Treatment Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Consumables and Assay Kits
• Instruments
• Services
• 6.2. Global Autoimmune Treatment Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Consultation and Diagnosis
• Therapy and monitoring
• Drug development
• 6.3. Global Autoimmune Treatment Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Rheumatoid Arthritis
• Systemic Lupus Erythematosus
• Sjogren's Syndrome
• Thyroiditis
• Scleroderma
• Other Diseases
• 6.4. Global Autoimmune Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Anti-Inflammatory
• Anti-Hyperglycemic
• NSAIDs
• Interferons
• Other Drug Class
• 6.5. Global Autoimmune Treatment Market, Sub-Segmentation Of Consumables And Assay Kits, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• ELISA Kits
• Reagents And Antibodies
• Sample Collection Kits
• 6.6. Global Autoimmune Treatment Market, Sub-Segmentation Of Instruments, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Diagnostic Equipment
• Imaging Systems
• 6.7. Global Autoimmune Treatment Market, Sub-Segmentation Of Services, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Testing And Diagnostics Services
• Consultation And Support Services
• Data Analysis And Interpretation Services

7. Autoimmune Treatment Market Regional And Country Analysis

• 7.1. Global Autoimmune Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Autoimmune Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Autoimmune Treatment Market

• 8.1. Asia-Pacific Autoimmune Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Autoimmune Treatment Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Autoimmune Treatment Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Autoimmune Treatment Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Autoimmune Treatment Market

• 9.1. China Autoimmune Treatment Market Overview
• 9.2. China Autoimmune Treatment Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Autoimmune Treatment Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Autoimmune Treatment Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Autoimmune Treatment Market

• 10.1. India Autoimmune Treatment Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Autoimmune Treatment Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Autoimmune Treatment Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Autoimmune Treatment Market

• 11.1. Japan Autoimmune Treatment Market Overview
• 11.2. Japan Autoimmune Treatment Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Autoimmune Treatment Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Autoimmune Treatment Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Autoimmune Treatment Market

• 12.1. Australia Autoimmune Treatment Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Autoimmune Treatment Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Autoimmune Treatment Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Autoimmune Treatment Market

• 13.1. Indonesia Autoimmune Treatment Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Autoimmune Treatment Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Autoimmune Treatment Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Autoimmune Treatment Market

• 14.1. South Korea Autoimmune Treatment Market Overview
• 14.2. South Korea Autoimmune Treatment Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Autoimmune Treatment Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Autoimmune Treatment Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Autoimmune Treatment Market

• 15.1. Western Europe Autoimmune Treatment Market Overview
• 15.2. Western Europe Autoimmune Treatment Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Autoimmune Treatment Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Autoimmune Treatment Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Autoimmune Treatment Market

• 16.1. UK Autoimmune Treatment Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Autoimmune Treatment Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Autoimmune Treatment Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Autoimmune Treatment Market

• 17.1. Germany Autoimmune Treatment Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Autoimmune Treatment Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Autoimmune Treatment Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Autoimmune Treatment Market

• 18.1. France Autoimmune Treatment Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Autoimmune Treatment Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Autoimmune Treatment Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Autoimmune Treatment Market

• 19.1. Italy Autoimmune Treatment Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Autoimmune Treatment Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Autoimmune Treatment Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Autoimmune Treatment Market

• 20.1. Spain Autoimmune Treatment Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Autoimmune Treatment Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Autoimmune Treatment Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Autoimmune Treatment Market

• 21.1. Eastern Europe Autoimmune Treatment Market Overview
• 21.2. Eastern Europe Autoimmune Treatment Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Autoimmune Treatment Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Autoimmune Treatment Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Autoimmune Treatment Market

• 22.1. Russia Autoimmune Treatment Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Autoimmune Treatment Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Autoimmune Treatment Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Autoimmune Treatment Market

• 23.1. North America Autoimmune Treatment Market Overview
• 23.2. North America Autoimmune Treatment Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Autoimmune Treatment Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Autoimmune Treatment Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Autoimmune Treatment Market

• 24.1. USA Autoimmune Treatment Market Overview
• 24.2. USA Autoimmune Treatment Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Autoimmune Treatment Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Autoimmune Treatment Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Autoimmune Treatment Market

• 25.1. Canada Autoimmune Treatment Market Overview
• 25.2. Canada Autoimmune Treatment Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Autoimmune Treatment Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Autoimmune Treatment Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Autoimmune Treatment Market

• 26.1. South America Autoimmune Treatment Market Overview
• 26.2. South America Autoimmune Treatment Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Autoimmune Treatment Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Autoimmune Treatment Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Autoimmune Treatment Market

• 27.1. Brazil Autoimmune Treatment Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Autoimmune Treatment Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Autoimmune Treatment Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Autoimmune Treatment Market

• 28.1. Middle East Autoimmune Treatment Market Overview
• 28.2. Middle East Autoimmune Treatment Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Autoimmune Treatment Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Autoimmune Treatment Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Autoimmune Treatment Market

• 29.1. Africa Autoimmune Treatment Market Overview
• 29.2. Africa Autoimmune Treatment Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Autoimmune Treatment Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Autoimmune Treatment Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Autoimmune Treatment Market Competitive Landscape And Company Profiles

• 30.1. Autoimmune Treatment Market Competitive Landscape
• 30.2. Autoimmune Treatment Market Company Profiles
  • 30.2.1. Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Autoimmune Treatment Market Other Major And Innovative Companies

• 31.1. Hoffmann-La Roche AG
• 31.2. AstraZeneca PLC
• 31.3. Bristol-Myers Squibb Company
• 31.4. Autoimmune Inc.
• 31.5. Siemens Healthcare Private Limited
• 31.6. Thermo Fisher Scientific Inc.
• 31.7. Biogen Idec Inc.
• 31.8. Bayer Schering Pharma AG
• 31.9. GSK PLC
• 31.10. Genentech Inc.
• 31.11. AbbVie Inc.
• 31.12. Celgene Corporation
• 31.13. Gilead Sciences Inc.
• 31.14. Merck & Co. Inc.
• 31.15. Novartis International AG

32. Global Autoimmune Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Autoimmune Treatment Market

34. Recent Developments In The Autoimmune Treatment Market

35. Autoimmune Treatment Market High Potential Countries, Segments and Strategies

• 35.1 Autoimmune Treatment Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Autoimmune Treatment Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Autoimmune Treatment Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer